Loading clinical trials...

Efficacy and Safety of a Drinkable Nutraceutical for Hair Loss in Patients Using GLP-1/GIP Receptor Agonists | Clinical Trials | Clareo Health

RECRUITINGNA

Efficacy and Safety of a Drinkable Nutraceutical for Hair Loss in Patients Using GLP-1/GIP Receptor Agonists

Evaluation of the Efficacy and Safety of a Drinkable Nutraceutical in Improving Hair Loss in Patients Treated With GLP-1/GIP Receptor Agonists: a Double-blind, 1:1 Randomized, Placebo-controlled Study.

NCT07484061•Olistic Research Labs S.L.

View on ClinicalTrials.gov

Summary

The purpose of this clinical trial is to evaluate the efficacy of Olistic© Next Women, a nutraceutical supplement, compared with placebo in improving hair loss in patients undergoing treatment with GLP-1/GIP agonists. This 6-month, randomized, placebo-controlled clinical study investigates whether daily supplementation with Olistic© Next Women leads to significant improvements in hair loss in this patient population. In addition, the study assesses the safety and tolerability of the product throughout the treatment period.

Eligibility

Age

35 - No limit years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Female gender.
•Age \>35 years.
•Initiation of treatment with a GLP-1/GIP agonist, or treatment duration \< 3 months, as per routine clinical practice in the endocrinology clinic.
•Having signed the participant information sheet and the written informed consent and having been informed of the objective of the study.
•Additional criteria to be included by the client.

Exclusion Criteria

•Allergy or hypersensitivity to any of the components of the product, or to a product from a similar category to the one being tested.
•Scalp diseases: cicatricial alopecia, alopecia areata, folliculitis decalvans, psoriasis, moderate to severe seborrheic dermatitis, eczema, cancer, etc.
•Women presenting alopecia due to an underlying medical condition (hypothyroidism, anemia, lupus, etc.).
•Pharmacological treatment that may promote the onset of telogen effluvium, initiated within the 3 months prior to study start (e.g., valproic acid, carbamazepine, phenytoin, selective serotonin reuptake inhibitors, oral anticoagulants, retinoids, beta-blockers). Patients who have undergone a dose change of these medications within the same period are also excluded.
•Women with uncontrolled thyroid disorders (hyperthyroidism or hypothyroidism) within the 6 months prior to study initiation.
•Women who have used anti-hair loss products within the last 3 months.
•Women who have initiated or undergone dermatological treatment for hair loss within the last 6 months (minoxidil, finasteride, PRP, mesotherapy, etc.).
•Women who have undergone hair transplantation within the 18 months prior to study initiation.
•Women who have initiated treatment with anxiolytics, antidepressants, amphetamines, ACE inhibitors, or iron within the last 3 months.
•Women who initiated or discontinued hormonal treatment (oral contraceptives, oral or topical hormone replacement therapy, ovarian stimulation) within the 3 months prior to study initiation.
+2 more criteria

Locations (1)

Grupo Dermatologico Y Estetico Pedro Jaen S.A.

Madrid, Madrid, Spain

Key Dates

Start Date

March 9, 2026

Primary Completion Date

August 31, 2026

Completion Date

October 31, 2026

Last Updated

March 19, 2026

Enrollment

ESTIMATED participants

Conditions

Telogen Effluvium

Interventions

Drinkable multifactorial food supplement containing vitamins, minerals, amino acids, plant extracts, and other bioactive compounds, formulated to support hair growth and scalp health in women +45.

DIETARY_SUPPLEMENT

Placebo control

OTHER